Labcorp Reports Strong Q3 2026 Earnings & Raises Full-Year Guidance

Overview

On October 28, 2026, Labcorp Holdings Inc. (NYSE: LH) filed a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) announcing financial results for the third quarter ended September 30, 2026, and updating full-year 2026 financial guidance.

Key Q3 2026 Financial Highlights

• Revenue: Reached $3.810 billion, an increase of 6.9% compared to $3.564 billion in Q3 2025. Organic revenue growth contributed 5.5%, while acquisitions net of divestitures contributed 1.5%.
• Operating Income: Stood at $402.1 million (10.6% of revenue) versus $396.6 million (11.1% of revenue) in Q3 2025.
• Adjusted Operating Income (AOI): Rose to $570.0 million (15.0% margin), compared to $513.3 million (14.4% margin) in Q3 2025, driven by organic growth and operational efficiencies.
• Diluted EPS: Reported at $3.22, up 3.3% from $3.12 in Q3 2025.
• Adjusted EPS: Rose 14.5% to $4.78 from $4.18 in Q3 2025.

Raised Full-Year 2026 Guidance

• Enterprise Revenue Growth: Updated to a range of 5.9% to 6.7% (an increase of 50 basis points at the midpoint).
• Adjusted EPS: Raised to a range of $18.30 to $18.70 (up $0.18 at the midpoint).

Strategic Updates & Capital Allocation

• M&A Activity: Labcorp closed the acquisition of MLM Medical Labs and announced agreements to acquire select assets of BioReference Health, Myriad Genetics' Prenatal Health business, and Millennium Health. All transactions are expected to be accretive to adjusted EPS in year one.
• Specialty Pipeline: Secured FDA approval of PGDx elio® tissue complete CDx as a companion diagnostic for advanced melanoma, launched the Elecsys® pTau-217 blood test for Alzheimer's disease, and entered collaborations for bladder cancer and HPV testing.
• Capital Returns: Invested $255.5 million in acquisitions, paid $58.2 million in dividends during the quarter, declared a quarterly dividend of $0.72 per share payable December 11, 2026, and maintained $1.4 billion remaining in share repurchase authorization.